Expanded Access for BLZ-100 (Tozuleristide)
NCT04343274 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-04-04
Summary
This is the Blaze Bioscience expanded access program for its investigational drug tozuleristide intended for patients with life-threatening diseases or conditions who have exhausted approved treatment options and are unable to participate in a clinical trial involving the investigational drug tozuleristide.
Interventions
- DRUG
-
Tozuleristide
Sponsors & Collaborators
-
Blaze Bioscience Inc.
lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
NCT06915766 ·Status: AVAILABLE
-
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
NCT04355793 ·Status: NO_LONGER_AVAILABLE
-
Tocilizumab for the Treatment of Refractory Behcet's Uveitis
NCT03554161 ·Status: TERMINATED ·Phase: PHASE2
-
Severe Bullous Drug Eruption and Filgrastim
NCT04651439 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT03674047 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
NCT01573533 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
NCT04347226 ·Status: TERMINATED ·Phase: PHASE2
-
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
NCT05544032 ·Status: AVAILABLE
-
B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency
NCT00024934 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants
NCT04828343 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
NCT03240133 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY3478006 in Healthy Participants
NCT04230122 ·Status: TERMINATED ·Phase: PHASE1
-
Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)
NCT04723589 ·Status: WITHDRAWN ·Phase: PHASE2
-
Gene Therapy for Chronic Granulomatous Disease
NCT00394316 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Study of LY3549492 in Healthy Participants
NCT04758234 ·Status: COMPLETED ·Phase: PHASE1
-
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
NCT06082323 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Clinical Activity of Itolizumab in aGVHD
NCT05823675 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
NCT06462469 ·Status: RECRUITING ·Phase: PHASE4
-
Low-dose IL-2 Treatment on Behcet's Disease
NCT04065672 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
NCT03923738 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03827798 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Subcutaneous Pharmacokinetics of Belatacept
NCT00569803 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
NCT03203369 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
NCT00472030 ·Status: COMPLETED ·Phase: PHASE4